Altimmune (ALT) Net Income towards Common Stockholders (2016 - 2025)
Historic Net Income towards Common Stockholders for Altimmune (ALT) over the last 17 years, with Q3 2025 value amounting to -$19.0 million.
- Altimmune's Net Income towards Common Stockholders rose 1676.95% to -$19.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$84.0 million, marking a year-over-year increase of 1882.44%. This contributed to the annual value of -$95.1 million for FY2024, which is 752.99% down from last year.
- Latest data reveals that Altimmune reported Net Income towards Common Stockholders of -$19.0 million as of Q3 2025, which was up 1676.95% from -$22.1 million recorded in Q2 2025.
- In the past 5 years, Altimmune's Net Income towards Common Stockholders ranged from a high of -$14.9 million in Q1 2021 and a low of -$33.5 million during Q3 2021
- In the last 5 years, Altimmune's Net Income towards Common Stockholders had a median value of -$22.1 million in 2025 and averaged -$22.4 million.
- In the last 5 years, Altimmune's Net Income towards Common Stockholders plummeted by 28253.86% in 2021 and then surged by 2983.29% in 2022.
- Over the past 5 years, Altimmune's Net Income towards Common Stockholders (Quarter) stood at -$23.9 million in 2021, then grew by 9.33% to -$21.7 million in 2022, then tumbled by 46.08% to -$31.6 million in 2023, then increased by 26.37% to -$23.3 million in 2024, then rose by 18.39% to -$19.0 million in 2025.
- Its last three reported values are -$19.0 million in Q3 2025, -$22.1 million for Q2 2025, and -$19.6 million during Q1 2025.